Edap Tms S.a.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EDAP research report →
Range $10 – $10
Price Chart
About the company
EDAP TMS S. A. , together with its subsidiaries, develops, manufactures, promotes, and distributes minimally-invasive medical devices for urology based upon proprietary ultrasound technology in Asia, France, the United States, and internationally.
- CEO
- Ryan Rhodes
- IPO
- 1997
- Employees
- 289
- HQ
- Vaulx-en-Velin, FR
Get TickerSpark's AI analysis on EDAP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $178.23M
- P/E
- -2.66
- Fwd P/E
- 34.27
- PEG
- 0.05
- P/S
- 1.56
- P/B
- 3.10
- EV/EBITDA
- -2.77
- Div Yield
- 0.00%
- Gross Margin
- 47.59%
- Op Margin
- -46.54%
- Net Margin
- -59.75%
- ROE
- -241.01%
- ROIC
- -38.23%
Latest fiscal year · YoY change
- Revenue
- $70.75M+10.3%
- Gross Profit
- $30.09M+13.3%
- Op Income
- $-25,208,760
- Net Income
- $-29,336,493-54.3%
- EPS
- $-0.78-52.9%
- OCF Growth
- -20.8%
- FCF Growth
- -25.3%
- 52W High
- $5.05
- 52W Low
- $1.21
- 50D MA
- $3.74
- 200D MA
- $3.17
- Beta
- -0.08
- RSI (14)
- 72
- Avg Volume
- 39.24K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
FocalTherics posted 26% revenue growth in Q3 on higher system sales and treatment revenue, but missed its expected timing on three capital deals and narrowed full-year guidance.· November 5, 2026
- Q3 HIFU revenue was about $9.8 million, up 26% year over year, with gross margin improving to 51.4% from 46.6%.
- The quarter included seven Focal One capital system sales versus six a year ago, plus one net operating lease placement, bringing the install base to 192 systems.
- U.S. procedures grew 32% year over year, and management said utilization remains supported by an expanding install base and better reimbursement.
- Revenue came in below plan because three anticipated system sales slipped into Q4 due to longer hospital approval cycles and one banking-related delay.
- Management narrowed 2026 revenue guidance to $50 million-$52 million from $50 million-$54 million and said cash rose to $56.3 million after the August equity raise.
Third quarter 2026 HIFU revenue was $9.8 million, up 26% from $7.8 million in the third quarter of 2025. Gross margin was 51.4% versus 46.6% a year ago, an increase of 482 basis points. Operating expenses were $12.8 million versus $10.3 million, operating loss was $7.8 million versus $6.7 million, and net loss was $4.5 million, or $0.10 per share, versus $5.9 million, or $0.16 per share, in Q3 2025. Cash and cash equivalents ended the quarter at $56.3 million, up from $21.5 million in Q2, reflecting the August equity raise. Full-year 2026 revenue guidance was narrowed to $50 million-$52 million, which management said implies 34%-39% growth over 2025, down from the prior $50 million-$54 million range.
Ryan Rhodes framed the quarter as continued execution on Focal One’s 2026 growth strategy, emphasizing broader adoption at existing health systems, new account wins, reimbursement progress, and pipeline growth. He said the missed revenue was entirely due to timing, not demand, and highlighted wins such as additional systems within Baylor Scott & White, entry into Maine, expansion at Kaiser, and international momentum in Turkey, Mexico, and France. His tone was confident and constructive, with repeated emphasis that the company is building a multi-indication platform and a long-term focal therapy category.
Ken Mobeck said the revenue beat/miss dynamics were tied to capital timing, with three systems expected in Q3 now forecast for Q4, and he pointed to strong underlying demand and a strong pipeline. He highlighted gross margin improvement to 51.4% from 46.6%, driven by lower standard cost and higher average selling prices for systems and Focalpaks. He also noted cash of $56.3 million at quarter-end after the August equity raise, and said the company is well positioned financially to execute its priorities.
Analysts pressed management on why three system sales slipped and whether forecasting has changed. Management said the deals were delayed by hospital committee approval timing and, in one case, bank-related financing issues; Ryan said one sale has already closed and two POs have been signed, and management said the pipeline remains strong and Q4 should finish well. Analysts also asked about the HIFUSA study and procedure growth into 2027; management said HIFUSA is a phase III randomized trial with 14 centers and 108 patients, with data expected early next year, and said procedure growth should remain consistent, though Q4 is seasonally the biggest quarter and ramping new systems takes time.
The call showed broad-based commercial momentum: more system placements, higher utilization, and growing adoption inside existing health systems, plus early traction internationally. Management also pointed to improving reimbursement, including salvage-treatment coverage from several commercial payers and universal coverage in France, which could support longer-term demand.
The main risk on the call was execution timing: revenue fell short because three expected system sales slipped, and management acknowledged hospital committee and financing delays can push deals between quarters. Management also signaled that procedure growth should be modeled cautiously because new systems take time to ramp and Q4 seasonality is important, while broader guidance was narrowed, not raised.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.5%
- Shares Outstanding
- 37.48M
- Float Shares
- 37.28M
of shares held by institutions
42 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Soleus Capital Management, L.P. | 7.31M | 0 |
| Flax Pond Capital, LLC | 736.23K | ▼ 47.22K |
| Bruce & Co., Inc. | 438.65K | 0 |
| Summit Trail Advisors, LLC | 82.34K | ▼ 20.00K |
| Citadel Advisors LLC | 66.18K | ▲ 66.18K |
| Schonfeld Strategic Advisors LLC | 41.73K | ▲ 15.87K |
| Manatuck Hill Partners, LLC | 27.60K | 0 |
| Intrepid Family Office LLC | 25.00K | 0 |
| Susquehanna International Group, Llp | 22.19K | ▲ 22.19K |
| Cibc Private Wealth Group LLC | 8.00K | ▼ 2.00K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 1, 26 | Levy Guy | other | 0 |
| Apr 11, 30 | Levy Guy | other | 0 |
| Jan 1, 26 | Levy Guy | other | 0 |
| Aug 14, 26 | Horn David R. | buy | 10,000 |
| Aug 14, 26 | LEVINE JOSHUA | buy | 10,000 |
| Aug 14, 26 | Mobeck Kenneth S. | buy | 5,000 |
| Aug 14, 26 | Annen Steven | buy | 5,000 |
| May 12, 26 | Annen Steven | other | 90,000 |
| May 12, 26 | Annen Steven | other | 100,000 |
| May 12, 26 | Shah Sanket | other | 75,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our EDAP coverage
Recent articles, reports, and earnings notes.
No research on EDAP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EDAP report →EDAP TMS S.A. (FOCL) Presents at 2026 UBS Global Healthcare Conference Transcript
seekingalpha.com · Nov 10
EDAP TMS S.A. (FOCL) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 8
EDAP TMS S.A. (FOCL) Q2 2026 Earnings Call Transcript
seekingalpha.com · Aug 13
McDonald's Corp (MCD) (Q2 2026) Earnings Call Highlights: Navigating US Execution Challenges While Driving Global Growth
gurufocus.com · Aug 4
Edap Tms Unveils FocalTherics Pivot, Targets 40% Growth on HIFU Expansion
marketbeat.com · Jun 1
EDAP Announces Corporate Name Change to FocalTherics™ to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy
globenewswire.com · May 29
EDAP Announces Corporate Name Change to FocalTherics™ to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy
globenewswire.com · May 29
EDAP | Focal One to Present at Jefferies 2026 Global Healthcare Conference
globenewswire.com · May 21
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.